Journal of Antimicrobial Chemotherapy (1996) 37, 555-564
© 1996 The British Society for Antimicrobial Chemotherapy
research-article |
Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia
aHospital General de Mexico Mexico City, Mexico bRobert Reid Cabral Children's Hospital Santo Domingo, Dominican Republic cGlaxo Wellcome Inc., Research Triangle Park North Carolina, USA
Received 3 July 1995; returned 15 September 1995; accepted 20 October 1995
*Correspondence to: Dr Jeffrey J. Collins, Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709, USA
Cefuroxime axetil has been evaluated previously in the treatment of lower respiratory tract infections, but not specifically in the treatment of community-acquired pneumonia. In a multicentre, investigator-blinded clinical trial, 162 patients with community-acquired pneumonia were randomly assigned to receive orally either cefuroxime axetil 500 mg bid (n = 84) or amoxycillin/clavulanate 500 mg/125 mg tid (n = 78) for 10 days. Organisms were isolated from the pretreatment sputum specimens of 97 of 162 (60%) patients, the commonest isolates being Streptococcus pneumoniae (38%) and Haemophilus influenzae (18%). A satisfactory clinical outcome (cure or improvement) was achieved in 100% (55 of 55) and 96% (49 of 51) of the clinically evaluable patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively (P = 0.23). With respect to eradication of bacterial pathogens, a satisfactory outcome (cure, presumed cure or cure with colonization) was obtained in 94% (32 of 34) and 93% (37 of 40) of bacteriologically evaluable patients treated with cefuroxime axetil or amoxycillin/clavulanate, respectively (P=1.00). Both treatment regimens used in this study were well tolerated. The most common drug-related adverse experiences were gastrointestinal events, reported by 8% and 4%, respectively, of the patients in the amoxycillin/clavulanate and cefuroxime axetil groups, a difference which was not statistically significant (P = 0.32). These results indicate that cefuroxime axetil twice a day is as effective as amoxycillin/clavulanate three times a day in the treatment of outpatients with mild to moderate community-acquired pneumonia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W S Lim, S V Baudouin, R C George, A T Hill, C Jamieson, I Le Jeune, J T Macfarlane, R C Read, H J Roberts, M L Levy, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009 Thorax, October 1, 2009; 64(Suppl_3): iii1 - iii55. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Maimon, C. Nopmaneejumruslers, and T. K. Marras Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis Eur. Respir. J., May 1, 2008; 31(5): 1068 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Martin, S. Quilici, T. File, J. Garau, A. Kureishi, and M. Kubin Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance J. Antimicrob. Chemother., May 1, 2007; 59(5): 977 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults Thorax, December 1, 2001; 56(90004): iv1 - 64. [Full Text] [PDF]
|
|